A protein called FPGS drives breast cancer growth by triggering a cellular cleanup process that helps tumors survive, and blocking FPGS or related proteins stopped cancer cell growth in laboratory and animal studies. According to Gram Research analysis, FPGS is significantly overactive in breast cancer tissues and high levels predict worse patient survival, making it a promising new target for future breast cancer treatments.
Scientists have discovered that a protein called FPGS, which helps cells hold onto folate (a B vitamin), is overactive in breast cancer and drives tumor growth. According to Gram Research analysis, high levels of FPGS are linked to worse survival rates in breast cancer patients. The research shows that FPGS works by triggering a cellular cleanup process called mitophagy, which paradoxically helps cancer cells survive and multiply. Importantly, blocking FPGS or the proteins it works with stopped cancer growth in lab and animal studies, suggesting a new way to treat breast cancer in the future.
Key Statistics
A 2026 research study published in Cellular Signalling found that FPGS protein is markedly upregulated in breast cancer tissues and that high FPGS expression is associated with poor patient survival outcomes.
In laboratory and animal studies, blocking CDK9 (a protein stabilized by FPGS) suppressed breast cancer cell proliferation and significantly reduced tumor growth in mice with breast cancer.
The 2026 research identified the FPGS-CDK9-mTOR axis as a critical regulator of mitophagy and breast cancer progression, suggesting FPGS as both a diagnostic biomarker and potential therapeutic target.
The Quick Take
- What they studied: How a protein called FPGS helps breast cancer cells grow and survive, and whether blocking it could stop tumors
- Who participated: The study used breast cancer tissue samples and cancer cells grown in the lab, plus mouse models with breast cancer tumors
- Key finding: FPGS is much more active in breast cancer tissues than normal tissue, and high FPGS levels predict worse patient outcomes. Blocking FPGS or related proteins stopped cancer cell growth and tumor development
- What it means for you: This research identifies a new potential target for breast cancer treatment, though human clinical trials are still needed before this becomes a therapy. The findings may eventually lead to better diagnostic tests and new drug options for breast cancer patients
The Research Details
Researchers examined breast cancer tissue samples and found that FPGS protein levels were significantly higher in cancer cells compared to healthy tissue. They then used cultured breast cancer cells in the laboratory to test how FPGS affects cell growth and survival. To understand the mechanism, they tracked how FPGS interacts with other proteins inside cells, particularly a protein called CDK9. Finally, they tested whether blocking FPGS or CDK9 could slow tumor growth in mice with breast cancer, measuring tumor size and growth rates over time.
The study combined multiple research approaches: analyzing patient tissue samples, conducting laboratory experiments with cancer cells, studying protein interactions at the molecular level, and testing potential treatments in living animals. This multi-layered approach helps confirm that the findings are real and not just laboratory artifacts.
Understanding how cancer cells fuel their own growth is crucial for developing new treatments. This research reveals a specific pathway that breast cancer cells depend on, which could be targeted with drugs. By identifying FPGS as a key player, scientists have found a potential weak point in breast cancer’s survival strategy that could be exploited therapeutically
The research was published in Cellular Signalling, a peer-reviewed scientific journal. The study used multiple experimental approaches to confirm findings, which strengthens confidence in the results. However, the research was conducted primarily in laboratory settings and animal models, so results may not directly translate to human patients. Human clinical trials would be needed to confirm whether blocking FPGS is safe and effective in people with breast cancer
What the Results Show
The research revealed that FPGS protein is dramatically overproduced in breast cancer tissues compared to normal breast tissue. Patients with high FPGS levels had worse survival outcomes, suggesting this protein is a marker of aggressive cancer. When researchers blocked FPGS in cancer cells grown in the lab, the cells stopped multiplying and growing. Similarly, when they used drugs to inhibit CDK9 (the protein that FPGS stabilizes), cancer cell growth was suppressed.
In mouse models with breast cancer tumors, treating the animals with CDK9 inhibitors significantly slowed tumor growth and reduced tumor size. This demonstrates that the FPGS-CDK9 pathway is not just active in isolated cells but actually drives real tumor development in living organisms. The researchers also showed that blocking mitophagy (the cellular cleanup process that FPGS triggers) had the same effect as blocking FPGS itself, confirming that this cleanup process is essential for cancer cell survival.
The study identified the precise molecular mechanism by which FPGS works: it binds to CDK9 and prevents the protein from being broken down, allowing CDK9 to accumulate inside cells. This accumulation of CDK9 then triggers excessive mitophagy, a process where cells consume their own damaged mitochondria (the cell’s energy factories). While mitophagy is normally a healthy cellular process, cancer cells hijack it to remove damaged components that would otherwise trigger cell death. The research also showed that FPGS levels could serve as a diagnostic marker to identify which breast cancer patients have more aggressive tumors
Previous research has shown that cancer cells reprogram their metabolism to support rapid growth, but the specific role of folate metabolism in this process was unclear. This study fills that gap by demonstrating that FPGS, an enzyme in folate metabolism, is a critical driver of breast cancer progression. The findings align with growing evidence that mitophagy is abnormally active in cancer cells, but this is the first study to connect FPGS to this process in breast cancer. The CDK9 protein has been studied in other cancers, but its interaction with FPGS in breast cancer is novel
The study was conducted primarily in laboratory cell cultures and mouse models, which do not perfectly replicate human breast cancer. The sample size of patient tissue samples analyzed was not specified in the abstract, making it difficult to assess how representative the findings are. The research does not yet show whether FPGS inhibitors would be safe or effective in human patients. Additionally, the study focused on one specific type of breast cancer pathway, so the findings may not apply equally to all breast cancer subtypes. Long-term effects of blocking FPGS or CDK9 in humans remain unknown
The Bottom Line
Based on this research, FPGS shows promise as a therapeutic target for breast cancer, but it is too early to recommend any specific treatment changes. Patients with breast cancer should continue following their oncologist’s current treatment recommendations. Researchers should prioritize clinical trials testing CDK9 inhibitors or FPGS-targeting drugs in breast cancer patients. High confidence: FPGS is overactive in breast cancer and drives tumor growth. Moderate confidence: blocking FPGS could be an effective treatment strategy pending human trials
This research is most relevant to people with breast cancer and their doctors, as it may eventually lead to new treatment options. Researchers studying cancer metabolism and drug development should pay attention to FPGS as a potential drug target. Women at high risk for breast cancer may benefit from future diagnostic tests based on FPGS levels. This research is not yet actionable for the general public, as human clinical trials have not been conducted
Laboratory and animal studies typically take 2 to 5 years to complete. If promising results continue, researchers would then design human clinical trials, which could take 5 to 10 years or more. If a drug targeting FPGS or CDK9 proves safe and effective in trials, it could potentially reach patients within 10 to 15 years. Patients should not expect this to become a standard treatment in the immediate future
Frequently Asked Questions
What is FPGS and why does it matter for breast cancer?
FPGS is a protein that helps cells retain folate, a B vitamin. A 2026 study found FPGS is overactive in breast cancer and drives tumor growth by triggering excessive cellular cleanup. High FPGS levels predict worse survival, making it a potential treatment target.
Can FPGS be blocked to treat breast cancer?
Laboratory and animal studies show that blocking FPGS or related proteins stops cancer cell growth and tumor development. However, human clinical trials have not yet been conducted, so this is not yet an available treatment for breast cancer patients.
How does FPGS help cancer cells survive?
FPGS stabilizes a protein called CDK9, which triggers mitophagy, a cellular cleanup process. Cancer cells use this process to remove damaged components that would normally trigger cell death, allowing tumors to survive and grow.
When will FPGS-targeting drugs be available for patients?
Clinical trials would need to be conducted first, which typically takes 5 to 10 years or longer. If successful, an FPGS-targeting drug could potentially reach patients within 10 to 15 years, though this timeline is uncertain.
Should breast cancer patients get tested for FPGS levels?
FPGS testing is not yet a standard clinical practice. Patients should discuss with their oncologist whether FPGS testing might be available through clinical trials or research studies, but routine testing is not currently recommended.
Want to Apply This Research?
- Users with breast cancer could track FPGS biomarker levels (if tested by their oncologist) alongside tumor markers and treatment response metrics in a health app, recording results at each medical appointment to monitor disease progression
- While this research is not yet actionable for individual patients, users could use the app to log questions about emerging breast cancer treatments to discuss with their oncologist, and set reminders to stay informed about clinical trial opportunities for new therapies
- For patients enrolled in future clinical trials of FPGS or CDK9-targeting drugs, an app could track side effects, treatment adherence, and symptom changes over time, providing data to share with research teams and oncologists
This article summarizes research findings and is for educational purposes only. It does not constitute medical advice. Breast cancer is a serious disease requiring professional medical care. Patients should consult with their oncologist or healthcare provider before making any treatment decisions. The research described has been conducted in laboratory and animal models; human clinical trials are needed before any new treatments based on these findings can be recommended for patient use. Do not delay or avoid standard cancer treatment based on this information.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.